These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 15488964

  • 1. Efficacy of open-label venlafaxine in subjects with major depressive disorder: associations with neuroendocrine response to serotonergic and noradrenergic probes.
    Grossman R, Reynolds D, Goodman M, New A, Silverman J, Schmeidler J, Mitropoulou V, Siever LJ.
    Psychiatry Res; 2004 Sep 30; 128(2):203-6. PubMed ID: 15488964
    [Abstract] [Full Text] [Related]

  • 2. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS, Aguiar LM, Kunz NR, Lei D.
    J Psychiatr Res; 2004 Sep 30; 38(3):249-57. PubMed ID: 15003430
    [Abstract] [Full Text] [Related]

  • 3. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.
    J Psychopharmacol; 2009 Jul 30; 23(5):531-8. PubMed ID: 18635695
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder.
    Plesnicar BK.
    Psychiatr Danub; 2010 Sep 30; 22(3):413-7. PubMed ID: 20856184
    [Abstract] [Full Text] [Related]

  • 5. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
    Bares M, Kopecek M, Novak T, Stopkova P, Sos P, Kozeny J, Brunovsky M, Höschl C.
    J Affect Disord; 2009 Nov 30; 118(1-3):94-100. PubMed ID: 19249105
    [Abstract] [Full Text] [Related]

  • 6. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A, Korotzer A, Gommoll C, Li D.
    Depress Anxiety; 2008 Nov 30; 25(10):854-61. PubMed ID: 18050245
    [Abstract] [Full Text] [Related]

  • 7. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B.
    Depress Anxiety; 2007 Nov 30; 24(1):1-14. PubMed ID: 16894619
    [Abstract] [Full Text] [Related]

  • 8. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA.
    J Clin Psychopharmacol; 2006 Oct 30; 26(5):482-8. PubMed ID: 16974189
    [Abstract] [Full Text] [Related]

  • 9. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.
    Amsterdam JD, Shults J.
    J Clin Psychopharmacol; 2008 Apr 30; 28(2):171-81. PubMed ID: 18344727
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan 30; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 11. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec 30; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 12. Pro-inflammatory biomakers in depression: treatment with venlafaxine.
    Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, Sinacore J, Devane CL.
    World J Biol Psychiatry; 2009 Dec 30; 10(4):313-23. PubMed ID: 19921973
    [Abstract] [Full Text] [Related]

  • 13. Venlafaxine for treatment-resistant unipolar depression.
    Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J.
    J Clin Psychopharmacol; 1994 Dec 30; 14(6):419-23. PubMed ID: 7884023
    [Abstract] [Full Text] [Related]

  • 14. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Dec 30; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 15. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
    Nemeroff CB, Thase ME, EPIC 014 Study Group.
    J Psychiatr Res; 2007 Dec 30; 41(3-4):351-9. PubMed ID: 16165158
    [Abstract] [Full Text] [Related]

  • 16. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Amsterdam JD, Shults J.
    J Affect Disord; 2009 May 30; 115(1-2):234-40. PubMed ID: 18694599
    [Abstract] [Full Text] [Related]

  • 17. Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications.
    Vanoli A, Lane C, Harrison C, Steen N, Young A.
    J Psychopharmacol; 2008 Jun 30; 22(4):434-40. PubMed ID: 18635723
    [Abstract] [Full Text] [Related]

  • 18. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M.
    Psychiatry Res; 2008 Oct 30; 161(1):116-20. PubMed ID: 18755514
    [Abstract] [Full Text] [Related]

  • 19. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C, Sivrioglu EY, Akgoz S, Eker SS, Kirli S.
    Hum Psychopharmacol; 2006 Jul 30; 21(5):337-45. PubMed ID: 16856215
    [Abstract] [Full Text] [Related]

  • 20. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study.
    Pollack MH, Worthington JJ, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF.
    Psychopharmacol Bull; 1996 Jul 30; 32(4):667-70. PubMed ID: 8993089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.